Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4W92J)

• Drug Name: TC-2216 Drug Info
• Synonyms: NNR Therapeutics; TC-5685; Nicotinic ACh modulators (schizophrenia), Targacept; Alpha-4 beta-2 neuronal nicotinic receptor (schizophrenia, depression), Targacept; Oral alpha-4/beta-2 neuronal nicotinic receptor stimulator (shizophrenia/depression), Targacept

Indication

Disease Entry	ICD 11	Status	REF
Mood disorder	6A60-6E23	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 10176607
  CAS Number: CAS 646055-67-6
  TTD Drug ID: DM4W92J

Molecule-Related Drug Atlas

Drug(s) Targeting Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Varenicline	DMMUOLJ	Drug dependence		Approved	[3]
Metocurine Iodide	DMZJYBW	Anaesthesia	9A78.6	Approved	[4]
AZD-1446	DM7B1AR	Alzheimer disease	8A20	Phase 2	[5]
TC-6499-12	DMWPI2U	Irritable bowel syndrome	DD91.0	Phase 2	[6]
Sofinicline	DM157U0	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[7]
CP-601927	DMKJFDM	Gastrointestinal disease	DE2Z	Phase 2	[8]
SUVN 911	DMZP671	Major depressive disorder	6A70.3	Phase 1	[9]
Dianicline	DMX2SHT	Tobacco dependence	6C4A.2	Discontinued in Phase 3	[10]
TC-2696	DMP1A4S	Pain	MG30-MG3Z	Discontinued in Phase 2	[11]
Ispronicline	DMKY2UE	Alzheimer disease	8A20	Discontinued in Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)	TTL1ATN	ACHA4_HUMAN; ACHB2_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT00583544) A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers. U.S. National Institutes of Health.
• [2] TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity.CNS Neurosci Ther.2008 Winter;14(4):266-77.
• [3] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [4] NMR study of general anesthetic interaction with nAChR beta2 subunit.Biophys J.2008 Mar 1;94(5):1681-8.
• [5] A randomized, double-blind, placebo-controlled crossover study of 4 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.Psychopharmacology (Berl). 2014 Mar;231(6):1251-65.
• [6] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [7] Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014 Aug;23(8):1157-63.
• [8] Toxicity study in juvenile rats with the alpha4beta2 nicotinic acetylcholine receptor partial agonist CP-601,927. Birth Defects Res B Dev Reprod Toxicol. 2011 Aug;92(4):323-32.
• [9] Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine alpha42 Receptor Antagonist for the Treatment of Depression. J Med Chem. 2020 Mar 26;63(6):2833-2853.
• [10] Dianicline, a novel 42 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial.Nicotine Tob Res.2011 Jan;13(1):1-6.
• [11] alpha4beta2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology. 2013 Aug;71:191-203.
• [12] Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. J Mol Neurosci. 2006;30(1-2):19-20.